Figure 2
VSV-S2 induced both humoral and cell-mediated immunity in hACE2-KI mice using different combination of administration route. (a) Schematic figure of immunogenicity study plan. (b) Serum spike-specific IgG titer of all cohorts at day 20 post primary vaccination. (c) Booster dose was administered in appropriate animal cohorts as indicated and serum spike-specific IgG titer was determined for all cohorts at day 35 post vaccination. (d) BAL spike-specific IgG titer on day 35 post-vaccination. (e) BAL spike-specific IgA titer determined on day 35 post-vaccination. (f) T cell response was determined by IFN-γ ELISpot on Day 35 post-vaccination. n = 5 for VSV-WT, n = 10 for VSV-S2, each spot represents one animal sample. Antibody titers are presented as geometric means. All other data are presented as means. Statistical significance of the difference among groups was determined through one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test (comparison across all groups. For all analyses, differences were considered to be significant with p < 0.05. Statistical significance was indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
